Destiny-Breast02: High Levels Of Efficacy Of T-Dxd In Previously Treated Her2+ Breast Cancer

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

Updated findings of T-DXd in DESTINY-Breast02 at ESMO Breast 2024

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study

European Society for Medical Oncology (ESMO)

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups

DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancer

SABCS 2022: Primary results of the randomized, phase 3 study DESTINY-Breast02 + Q & A

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

Total Health | Oncology

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer

European Society for Medical Oncology (ESMO)